研究单位：[1]Chinese Anti-Cancer Association[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China[3]First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing, China[4]Southwest Hospital, China Chongqing, Chongqing, China[5]Wuhan Tongji Hospital Wuhan, Hubei, China[6]Fudan University Shanghai Cancer Center Shanghai, Shanghai, China
This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen receptor-positive early breast cancer.
